CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
Q1 2026 vs. Q4 2025
How the institutions holding CNS Pharmaceuticals, Inc. changed between Q4 2025 and Q1 2026.
All holders in Q1 2026All holders in Q4 2025
| Measure | Q4 2025 | Q1 2026 | Change |
|---|---|---|---|
| Holders | 10 | 12 | +2 |
| Shares | 124.3K | 145.6K | +21.4K (+17.2%) |
| Value | $652.4K | $348.7K | −$303.7K (−46.5%) |
New holders (4)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q1 2026 but not at the end of Q4 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 23,189 | $55.7K | 0.00% |
| Tower Research Capital LLC (TRC) | 1,310 | $3.13K | 0.00% |
| Citigroup Inc | 1 | $2 | 0.00% |
| Caitong International Asset Management Co., Ltd | 1 | $2 | 0.00% |
Sold out (2)
Institutions that held CNS Pharmaceuticals, Inc. at the end of Q4 2025 and filed for Q1 2026 without it.
| Institution | Shares, Q4 2025 | Value, Q4 2025 |
|---|---|---|
| DRW Securities, LLC | 15,429 | $81.0K |
| Bank of America Corp | 4 | $21 |